The US antisense therapy market benefits from research into treatments for rare genetic and neurological conditions. Approved therapies targeting disorders such as spinal muscular atrophy, Duchenne muscular dystrophy, and selected forms of amyotrophic lateral sclerosis demonstrate established clinical applications for antisense technology.
The antisense therapy market was valued at US$ 6.17...
English
Arabic
French
Spanish
Portuguese
Deutsch
Turkish
Dutch
Italiano
Russian
Romaian
Greek